| Prev Close | 8.15 |
| Day Low/High | 8.12 / 8.36 |
| 52 Wk Low/High | 5.70 / 9.09 |
| Avg Volume | 36.90K |
| Exchange | NASDAQ |
| Shares Outstanding | 13.29M |
| Market Cap | 108.35M |
| EPS | -0.90 |
| P/E Ratio | 8.49 |
| Div & Yield | N.A. (N.A) |
Latest News
Oramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe And Well Tolerated In Phase Ib Study
Preparing to submit IND and commence U.S. FDA Phase IIb trial in 2017
Oramed Receives Additional $4 Million Milestone Payment From HTIT
Totaling $29.5 Million in payments from HTIT received to date
Oramed Receives Additional $4 Million Milestone Payment From HTIT
Totaling $25.5 M in payments from HTIT received to date
Oramed Announces $6.5 Million Milestone Payment From HTIT
Payment comes in wake of positive topline phase IIB results
Oramed Announces Positive Top-Line Results From Phase IIb Oral Insulin Study
All Primary Safety and Efficacy Endpoints Were Met; Conference Call Today at 11:00 am EDT
Oramed Receives Patent Term Adjustment Extending The Term Of Its U.S. Patent
Patent addresses platform technology for oral insulin capsule ORMD-0801
Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal
Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.
Oramed Signs Up To $50 Million Licensing And Investment Agreements For Oral Insulin Capsule In China
Receiving up to $38,000,000 + royalties for licensing deal and $12,000,000 for equity investment at $10.39 per share
Oramed Completes Randomization Of Over 50% Of Patients In Phase IIb Oral Insulin Study
180 Patients Expected to be Enrolled in Study
